World’s First Allogeneic Stem Cell Drug
CARTISTEM®, the Allogeneic Umbilical Cord Blood-derived MesenchymalStem Cell drug, is for the treatment of knee cartilage defects in patients with Osteoarthritis (ICRS grade IV) caused by degeneration or repetitive trauma.ICRS grade : A diagnostic grading tool for the knee cartilage defect.
CARTISTEM® has been approved of its commercial use
by the Ministry of Food & Drug Safety in January 2012.
Microfracture is an arthrosopic operation that involves drilling small holes in the subchondral bone.
The operation induces bleeding of stem cells from bone marrow into the defect area, which then leads to
regeneration of these stem cells into cartilage and bone of treated area.
The operation takes about 30 min~1 hour and requires hospitalization for about 2~3 days.
Total Knee Arthroplasty is an operation method for severely damaged osteoarthritis patients. The treatment can alleviate the pain and improve a range of motion by replacing with the artificial joint, providing an effective operation with insured results.
There are a total knee replacement for the entire joint and partial replacement that only replaces the damaged area. The total operation takes about 2 hours, requiring 3~4 weeks of hospitalization.
The operation involves removal of damaged cartilages and bone and the insertion of artificial joints.
While there are many types of artificial joints that can substitute for the knee joints depending on the materials and shapes,
all of them are classified into the following 3 types by the body parts which they replace;
While the effective period varies depending on the product, TKR is typically effective for about 15 years, and requires frequent post-operational visits to the hospital for examinations of infections. Total knee replacement may cause pain as the operation involves an opening of the joint and the excision of the bones, but the pain reduces after about 2~3 months.
cartilage and bone
Arrangement of the
artificial joint to the
Insertion of the
According to the medical law Article 53 Clause 3 and rule Article 4 on the evaluation of new medical technology, the evaluation result for the safety and effectiveness of new medical technology has been revised and announced as Announcement No. 2012-1 (January 2, 2012) by The Ministry of Health & Welfare as follows.
Bone Marrow Collection
Transplantation Using Support